Core Viewpoint - The article discusses the advancements and potential of Gestala Technology, a company focused on ultrasound brain-machine interface technology, which aims to provide non-invasive solutions for chronic pain management and other neurological conditions [6][9]. Company Overview - Gestala Technology recently secured 150 million yuan in angel funding, led by Guosheng Capital and Daotong Investment, to support the development of its first product and preliminary clinical trials [6]. - The company was founded in January 2023 by Peng Lei and Chen Tianqiao, with a team of approximately 15 experts from various fields including acoustics, neuroscience, and AI [6][10]. Technology Insights - The main focus of Gestala's technology is on non-invasive ultrasound brain imaging and neural modulation, which has gained attention due to its potential to create a "read-write" system for the brain [7][8]. - Ultrasound technology has unique advantages over other brain modulation methods, allowing for targeted stimulation of specific brain regions without damaging neurons [8]. - The mechanism involves converting mechanical waves into bioelectrical signals that can stimulate neurons, with the ability to target areas deep within the brain [8][9]. Clinical Applications - The initial clinical application for Gestala is chronic pain management, which has a large patient base and objective efficacy evaluation [9]. - Previous studies indicate that a single 45-minute ultrasound stimulation can reduce pain scores by 50%, with effects lasting 1-2 weeks [9]. - The company is also exploring applications for mental health conditions such as depression and PTSD, as well as neurodegenerative diseases like Alzheimer's [9]. Future Development Plans - Gestala's development strategy includes a phased approach: starting with non-invasive neural modulation, progressing to stable brain activity reading, and eventually integrating gene editing and protein engineering technologies [10]. - The company believes that China has unique advantages in clinical resources, trial costs, and manufacturing supply chains, which can facilitate its growth in the ultrasound brain-machine interface sector [10].